Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:32:45 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:MESO - MESOBLAST LTD SPON ADR EACH REP 10 ORD (REV SPLIT) - https://www.mesoblast.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MESO - Q0.114.59·23.990.115.95-0.13-0.8284.04,2463,60415.74  16.07  15.5521.49  9.6117:36:38Jan 2815 min RT 2¢

Recent Trades - Last 10 of 3604
Time ETExPriceChangeVolume
17:36:38Q16.390.315
16:56:50Q17.000.921
16:28:10Q16.950.87100
16:17:43Q15.75-0.331
16:10:04Q15.95-0.131
16:10:04Q15.95-0.131
16:10:04Q15.95-0.131
16:10:04Q15.95-0.131
16:04:43Q15.95-0.131
16:04:35Q15.95-0.131

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-28 18:54U:MESONews ReleaseRyoncil(TM) Net Revenues Increase for the Quarter to US$30M
2026-01-26 18:46U:MESONews ReleaseReal-World Commercial Experience with Ryoncil(TM) Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
2026-01-18 19:01U:MESONews ReleaseFDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
2026-01-08 18:47U:MESONews ReleaseRyoncil(TM) Sales Increase 60% in December Quarter to US$35.1M
2026-01-01 18:02U:MESONews ReleaseMesoblast Announces Changes to Board of Directors' Leadership Roles
2025-12-29 18:58U:MESONews ReleaseMesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
2025-12-16 11:53U:MESONews ReleaseBeyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
2025-12-11 18:22U:MESONews ReleaseIndependent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
2025-12-03 18:10U:MESONews ReleaseMesoblast Participation at Piper Sandler Conference
2025-11-24 18:40U:MESONews ReleaseMesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil(TM) Revenue
2025-11-20 18:33U:MESONews ReleaseMesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil(TM) as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
2025-11-17 01:52U:MESONews ReleaseJames M. O'Brien Appointed Chief Financial Officer at Mesoblast
2025-11-04 18:41U:MESONews ReleaseMesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
2025-10-19 19:48U:MESONews ReleaseRyoncil(TM) Net Revenues Increase 69% in Second Quarter Post Launch
2025-10-06 19:25U:MESONews ReleaseRyoncil(TM) Revenues Increase 66% in Second Quarter Post Launch
2025-10-02 21:05U:MESONews ReleaseRyoncil(TM) Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
2025-09-26 01:50U:MESONews ReleaseMesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
2025-09-14 21:19U:MESONews ReleaseSuccessful Commercial Launch of Ryoncil(TM) Highlighted at Global Healthcare Conferences
2025-09-03 21:47U:MESONews ReleaseMesoblast Enters Into Option To Issue US$50 Million Convertible Notes